overview of prospective phase 3 planb trial of 21-gene recurrence score® result in breast cancer
Published 8 years ago • 200 plays • Length 3:57Download video MP4
Download video MP3
Similar videos
-
3:18
5-year outcomes from planb: phase 3 trial of 21-gene recurrence score® result in breast cancer
-
4:16
impact of phase 3 planb trial on evidence-based clinical practice for breast cancer
-
2:23
current status and future prospective of trial assigning individualized options for treatment (rx)
-
2:45
paloma-3: phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
-
1:27
the value of an intermediate recurrence score® result in the oncotype dx® breast cancer assay
-
5:47
the impact of the oncotype dx® recurrence score® on treatment decisions in breast cancer patients
-
5:54
roxane: impact of 21-gene assay on treatment for early breast cancer
-
1:13:21
clinical outcomes in early breast cancer with a high 21-gene recurrence score tailorx rct
-
22:28
eric winer: the role of the 21 gene recurrence score in decision making for er breast cancer
-
0:38
the role of the oncotype dx assay in the management of patients with breast cancer
-
18:14
does 21-gene recurrence score assay testingchange decisions? dr. adher alsayed ( day 1)
-
2:03
identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
-
1:56
dealing with an "intermediate" breast cancer recurrence score?
-
1:17
dr. albain on the 21- and 70-gene assays in breast cancer
-
4:48
oncotype dx testing and the tailorx trial
-
19:50
3mensio ct pre-case planning: redo-tavr with prior evolut pro
-
16:16
esso 2010: oncotype dx classifier for breast cancer
-
1:01
larry norton on the use of chemotherapy for women with intermediate-risk breast cancer
-
8:23
steve shak, asco 2020: the oncotype dx breast recurrence score® test